MedTrace Logo

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

NCT01802073 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-09-21

Study results available
· View outcomes & findings →

Summary

Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.

Conditions

  • Primary Sclerosing Cholangitis

Interventions

DRUG

Oral Vancomycin

Sponsors & Collaborators

Principal Investigators

  • Kenneth Cox, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802073 on ClinicalTrials.gov